Overview

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a study where AZD3241 or placebo is given to patients with Parkinson's disease in a blinded and randomized assignment. The main objective is to see if safety and tolerability of the drug is acceptable.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca